FierceHealthcare names COTA, Inc. as one of its 2020 “Fierce 15” Companies
COTA, Inc. has been named by FierceHealthcare as one of the 2020 Fierce 15 Companies, designating it as one of the most promising healthcare companies in the industry.
CEO Corner: COTA’s Year in Review
At COTA, 2019 represented a year of collaboration, research, and innovation to advance the use of real-world evidence in cancer care and drug development. As we think about what’s ahead in 2020, COTA’s CEO Mike Doyle reflects on how activities this year set us up for future success and continued learning.
COTA Team Member Spotlight: Monica Matta
For this month’s Team Member Spotlight, we are excited to recognize Monica Matta, who was recently selected as the 2019 CO10 of the year! She brings passion and determination to COTA’s client relationships alongside her dedicated and growing team.
Science, Innovation, and Survivorship: The Atlantic’s People v. Cancer
Last month, COTA participated in The Atlantic’s People v. Cancer, an annual event that brings together researchers, providers, patients and innovators to illuminate stories from the frontlines of the cancer community.
COTA and Guardant Health Collaborate Using Real-World Data to Reveal Insights into Metastatic Colon Cancer and Prevalence of Biomarker Testing
Research Published in JCO Precision Oncology Found Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing
COTA Presents Posters at ASH Annual Meeting, Reviewing Complexities of Generating RWD and How it Complements Traditional Clinical Trial Data
Research Presented Alongside MMRF and HUMC Evaluates Opportunity for RWE to Study Patient Treatment & Outcomes in Routine Cancer Care
The Role of Data in Patient Care and Drug Development
This fall, COTA’s CEO Mike Doyle attended the Healthcare Leaders Conference in Dallas, TX, and the Future of Health Data Summit 2019 in Washington, DC. In his conversations, a few key takeaways stood out around innovations related to the use of meaningful data…
COTA Team Member Spotlight: Tanvi Pal
We are pleased to recognize Tanvi Pal in this month’s Team Member Spotlight! If you’re interested in learning more about Tanvi, why she likes working at COTA and her thoughts on the future of cancer care, read on…
How Real-World Evidence Can Validate TAILORx and Inform Cancer Care
The TAILORx study was a major landmark in setting a new standard of care for breast cancer patients. But how well do real world treatment and outcomes mirror that of the clinical trial?
Collaborating with our Frenemies
COTA’s medical and scientific teams recently participated in the 8th Annual Friends of Cancer Research Blueprint for Breakthrough Forum in Washington, DC with various stakeholders across the regulatory and RWE landscape.
